Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

Merle Myerson, Colleen Ngai, Jeffrey Jones, Steve Holleran, Rajasekhar Ramakrishnan, Lars Berglund, Henry N. Ginsberg

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B (apoB) in VLDL, intermediate density lipoprotein (IDL), and LDL and of triglycerides (TGs) in VLDL. Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. These effects were associated with reduced production of LDL-apoB, mainly as a result of reduced secretion of apoB-lipoproteins directly into the LDL density range. Statin therapy also reduced hepatic production of VLDL-TG. There were no effects of simvastatin on the fractional catabolic rates of VLDL-apoB or -TG or LDL-apoB. The basis for decreased VLDL-TG secretion during simvastatin treatment is not clear, but recent studies suggest that statins may activate peroxisomal proliferator-activated receptorα (PPARα). Activation of PPARα could lead to increased hepatic oxidation of fatty acids and less synthesis of TG for VLDL assembly.

Original languageEnglish (US)
Pages (from-to)2735-2744
Number of pages10
JournalJournal of Lipid Research
Volume46
Issue number12
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Simvastatin
Apolipoproteins B
Dyslipidemias
Lipoproteins
Hydroxymethylglutaryl-CoA Reductase Inhibitors
IDL Lipoproteins
Cross-Over Studies
Triglycerides
Therapeutics
Lipids
Liver
Medical problems
Metabolism
Type 2 Diabetes Mellitus
Fatty Acids
Chemical activation
Cholesterol
Placebos
Plasmas
Oxidation

Keywords

  • 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors
  • Diabetes mellitus
  • Hypertriglyceridemia
  • Low density lipoproteins
  • Statins
  • Triglycerides
  • Very low density lipoproteins

ASJC Scopus subject areas

  • Endocrinology

Cite this

Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. / Myerson, Merle; Ngai, Colleen; Jones, Jeffrey; Holleran, Steve; Ramakrishnan, Rajasekhar; Berglund, Lars; Ginsberg, Henry N.

In: Journal of Lipid Research, Vol. 46, No. 12, 12.2005, p. 2735-2744.

Research output: Contribution to journalArticle

Myerson, Merle ; Ngai, Colleen ; Jones, Jeffrey ; Holleran, Steve ; Ramakrishnan, Rajasekhar ; Berglund, Lars ; Ginsberg, Henry N. / Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. In: Journal of Lipid Research. 2005 ; Vol. 46, No. 12. pp. 2735-2744.
@article{9712df645aa94f07ad520f5fa9610338,
title = "Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia",
abstract = "HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B (apoB) in VLDL, intermediate density lipoprotein (IDL), and LDL and of triglycerides (TGs) in VLDL. Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. These effects were associated with reduced production of LDL-apoB, mainly as a result of reduced secretion of apoB-lipoproteins directly into the LDL density range. Statin therapy also reduced hepatic production of VLDL-TG. There were no effects of simvastatin on the fractional catabolic rates of VLDL-apoB or -TG or LDL-apoB. The basis for decreased VLDL-TG secretion during simvastatin treatment is not clear, but recent studies suggest that statins may activate peroxisomal proliferator-activated receptorα (PPARα). Activation of PPARα could lead to increased hepatic oxidation of fatty acids and less synthesis of TG for VLDL assembly.",
keywords = "3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors, Diabetes mellitus, Hypertriglyceridemia, Low density lipoproteins, Statins, Triglycerides, Very low density lipoproteins",
author = "Merle Myerson and Colleen Ngai and Jeffrey Jones and Steve Holleran and Rajasekhar Ramakrishnan and Lars Berglund and Ginsberg, {Henry N.}",
year = "2005",
month = "12",
doi = "10.1194/jlr.M500335-JLR200",
language = "English (US)",
volume = "46",
pages = "2735--2744",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia

AU - Myerson, Merle

AU - Ngai, Colleen

AU - Jones, Jeffrey

AU - Holleran, Steve

AU - Ramakrishnan, Rajasekhar

AU - Berglund, Lars

AU - Ginsberg, Henry N.

PY - 2005/12

Y1 - 2005/12

N2 - HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B (apoB) in VLDL, intermediate density lipoprotein (IDL), and LDL and of triglycerides (TGs) in VLDL. Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. These effects were associated with reduced production of LDL-apoB, mainly as a result of reduced secretion of apoB-lipoproteins directly into the LDL density range. Statin therapy also reduced hepatic production of VLDL-TG. There were no effects of simvastatin on the fractional catabolic rates of VLDL-apoB or -TG or LDL-apoB. The basis for decreased VLDL-TG secretion during simvastatin treatment is not clear, but recent studies suggest that statins may activate peroxisomal proliferator-activated receptorα (PPARα). Activation of PPARα could lead to increased hepatic oxidation of fatty acids and less synthesis of TG for VLDL assembly.

AB - HMG-CoA reductase inhibitors (statins) are effective lipid-altering drugs for the treatment of dyslipidemia in patients with type 2 diabetes mellitus. We conducted a randomized, double-blind, placebo-controlled, crossover design trial to determine the effects of simvastatin, 80 mg/day, on plasma lipid and lipoprotein levels and on the metabolism of apolipoprotein B (apoB) in VLDL, intermediate density lipoprotein (IDL), and LDL and of triglycerides (TGs) in VLDL. Simvastatin therapy decreased TG, cholesterol, and apoB significantly in VLDL, IDL, and LDL. These effects were associated with reduced production of LDL-apoB, mainly as a result of reduced secretion of apoB-lipoproteins directly into the LDL density range. Statin therapy also reduced hepatic production of VLDL-TG. There were no effects of simvastatin on the fractional catabolic rates of VLDL-apoB or -TG or LDL-apoB. The basis for decreased VLDL-TG secretion during simvastatin treatment is not clear, but recent studies suggest that statins may activate peroxisomal proliferator-activated receptorα (PPARα). Activation of PPARα could lead to increased hepatic oxidation of fatty acids and less synthesis of TG for VLDL assembly.

KW - 3-hydroxy-3-methyl glutaryl coenzyme A reductase inhibitors

KW - Diabetes mellitus

KW - Hypertriglyceridemia

KW - Low density lipoproteins

KW - Statins

KW - Triglycerides

KW - Very low density lipoproteins

UR - http://www.scopus.com/inward/record.url?scp=30744434654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=30744434654&partnerID=8YFLogxK

U2 - 10.1194/jlr.M500335-JLR200

DO - 10.1194/jlr.M500335-JLR200

M3 - Article

C2 - 16162940

AN - SCOPUS:30744434654

VL - 46

SP - 2735

EP - 2744

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 12

ER -